Navigation Links
Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
Date:7/28/2009

PRINCETON, N.J., July 28 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced the appointment of Daniel E. Leone as Vice President of Business Development. Mr. Leone will be responsible for Laureate's worldwide business development activities, including sales and marketing. He will be supporting the company's contract development, manufacturing, and bioprocessing business.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"We are pleased to welcome Dan to Laureate's Leadership Team," said Robert J. Broeze, Ph.D., President and CEO of Laureate. "Dan is a seasoned executive with more than 20 years of experience in business development and he brings an impressive background that includes broad international business development and management experience in contract manufacturing, pharmaceuticals and specialty chemicals. His capabilities include strong leadership, and strategic and organizational skills that have produced positive results in early stage and mature businesses."

Most recently Dan served as Executive Director of Contract Manufacturing at Ben Venue Laboratories where he was responsible for Sales, Marketing and New Business Development for its parenteral contract manufacturing services business. Prior to Ben Venue, Dan was the Vice President of Business Operations at Boehringer Ingelheim Chemicals where he was responsible for Sales, Marketing, New Business Development and Supply Chain Management for its active pharmaceutical ingredients business. Prior to BI, Dan held positions of increasing responsibility at Hoechst Corporation. While at Hoechst Dan served as their Global Director, Ventures in Hoechst's Research and Technology Division where he was responsible for general management of several early stage businesses. Dan earned an MBA from Duke University and Masters and Bachelors degrees in Chemical Engineering from Manhattan College.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact us at info@laureatepharma.com or visit www.laureatepharma.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Broeze

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=84360


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
2. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
3. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
4. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. Laureate Announces Manufacturing Agreement with Tolerx
7. Laureate Pharma to Add More Manufacturing Capacity
8. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
9. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
10. Laureate Pharma Reports Record Growth for 2007
11. Laureate Pharma Appoints Gary Swan as Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Creative Medical ... Kesari , MD, PhD, FANA, FAAN to the Company,s ... neurology and clinical trials to assist the Company,s clinical ... stroke. The AmnioStem product is a universal donor stem cell ... activity in animal models of stroke 1 .  ...
(Date:12/6/2016)... ... December 06, 2016 , ... ProMIS ... of precision treatments for neurodegenerative diseases, today announced the validated monoclonal antibody ... direct neurotoxic effect of prion-like forms of Amyloid beta (Aß) in vitro. ...
(Date:12/5/2016)... 5, 2016 Research and Markets has ... Technologies, Markets and Companies" to their offering. ... , , ... using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics ... are also based on biomarker. Currently the most important ...
(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
Breaking Biology Technology:
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/16/2016)... SANTA CLARA, Calif. , Nov. 16, 2016 /PRNewswire/ ... company enhancing user experience and security for consumer ... provider for the financial and retail industry, today ... more secure and convenient way to authenticate users ... now uses Sensory,s TrulySecure™ software which ...
Breaking Biology News(10 mins):